PreciseDx
PreciseDx is a pioneering company in cancer risk stratification, utilizing its proprietary AI platform, OncoIntelligence™, to provide rapid and accurate patient-specific risk assessments for breast cancer. Their flagship product, PreciseBreast™, integrates morphologic features and clinical factors to deliver reliable results in hours, significantly reducing the time and cost associated with traditional gene expression testing. With clinical validation in over 3,000 cases, PreciseDx aims to redefine cancer care by enabling oncologists to make informed treatment decisions swiftly, thereby improving patient outcomes and reducing anxiety. The company is positioned to lead in the oncology diagnostics market with its innovative approach and strong partnerships with medical societies.
PreciseDx
PreciseDx is a pioneering company in cancer risk stratification, utilizing its proprietary AI platform, OncoIntelligence™, to provide rapid and accurate patient-specific risk assessments for breast cancer. Their flagship product, PreciseBreast™, integrates morphologic features and clinical factors to deliver reliable results in hours, significantly reducing the time and cost associated with traditional gene expression testing. With clinical validation in over 3,000 cases, PreciseDx aims to redefine cancer care by enabling oncologists to make informed treatment decisions swiftly, thereby improving patient outcomes and reducing anxiety. The company is positioned to lead in the oncology diagnostics market with its innovative approach and strong partnerships with medical societies.
TL;DR
Product: PreciseBreast — AI-driven, morphology-based breast cancer risk-of-recurrence test
Platform: OncoIntelligence (Morphology Feature Array)
Clinical validation: Validated in >3,000 cases (company reports)
Funding: Series B announced June 5, 2025; recent $11M close led by Eventide
Regulatory / lab status: CLIA and New York State DOH assay validation reported
Company Overview
Problem Domain
Oncology diagnostics; cancer risk stratification for breast cancer
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
Series B announced June 5, 2025; company announced an $11M close led by Eventide on June 18, 2025 with participation from other strategic investors.
Investor Signal
“Participation from strategic diagnostics and healthcare investors including LabCorp, Quest Diagnostics, Merck Global Health Innovation Fund, Philips Health Technology Ventures, Agilent Technologies, IBM Ventures, Mount Sinai Health System”